IMR Press / FBE / Volume 7 / Issue 1 / DOI: 10.2741/724

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Renal transplantation in amyloidosis and MIDD

Show Less
1 Renal Section, Boston University School of Medicine, 650 Albany Str, 5th floor, Boston, MA, 02118, USA

*Author to whom correspondence should be addressed.

Academic Editors: Ogo Egbuna, Jean Francis

Front. Biosci. (Elite Ed) 2015, 7(1), 171–180;
Published: 1 January 2015

Amyloidosis and monoclonal immunoglobulin deposition disease, though rare entities, can wreak havoc on the architecture and functioning of the kidneys. These diseases have a predilection to cause severe renal dysfunction leading to end stage renal disease (ESRD). In recent years, the available treatments for these diseases have expanded and afflicted patients are living longer, but with advanced kidney disease. Because of the complex nature of the pathophysiology and treatment of these diseases, it can be very challenging for a clinician to determine whether or not it is appropriate to refer an affected individual for kidney transplantation.

Renal transplant
AL amyloid
AA amyloid
Familial Amyloidosis
Back to top